Prevalence of Metabolic Syndrome in Iranian Hemodialysis Patients: A Systematic Review and Meta-analysis
| Autor: | amin afsharimoghadam |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
medicine.medical_specialty
lcsh:R5-920 hemodialysis business.industry medicine.medical_treatment 030232 urology & nephrology Subgroup analysis medicine.disease Checklist metabolic syndrome kidney failure Clinical trial 03 medical and health sciences 0302 clinical medicine Systematic review Internal medicine Meta-analysis Cohort Medicine dialysis 030212 general & internal medicine Hemodialysis Metabolic syndrome business lcsh:Medicine (General) |
| Zdroj: | International Journal of Basic Science in Medicine, Vol 4, Iss 4, Pp 131-136 (2019) amin afsharimoghadam |
| Popis: | Introduction: Metabolic syndrome as one of the risk factors for cardiovascular diseases has recently been the focus of clinical studies. This study was conducted to determine the prevalence of metabolic syndrome in hemodialysis patients in Iran. Methods: The present systematic review was done using Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist. Case-control, cohort and crosssectional studies conducted in Iran were included. Clinical trials, case reports, letters to editors, systematic reviews, study protocols, narrative reviews, and case series were excluded. Subgroup analysis was conducted for determining the heterogeneity based on the participants as well as their gender. Meta-analysis was conducted using STATA version 14.0. Results: The prevalence of metabolic syndrome among 799 patients was 50% (95% CI: 47.0, 53.0, I2=50.6). The analysis of subgroups was conducted for determining the heterogeneity based on the participants as well as their gender. Based on the analysis of the subgroups using a random effects model, the prevalence of metabolic syndrome was found to be 44% and 55% in Iranian men and women undergoing hemodialysis, respectively. Conclusion: Given the high prevalence of metabolic syndrome in hemodialysis patients, it is advisable and logical that patients with chronic renal failure should be regularly evaluated for metabolic syndrome and cardiovascular risk factors both at the diagnosis time and afterwards. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|